Close Menu

exon arrays

The company hopes to replicate its early data in future studies, making a case that better early diagnosis can improve outcomes for patients with schizophrenia and bipolar disorder.

In Genome Research this week: molecular autopsies for sudden death, telomere methylation in Arabidopsis, and more.

By Justin Petrone
Longtime array rivals Affymetrix and Illumina last week introduced new chips targeting the exome, exonic variants in the protein-coding regions of the human genome.

The researchers found that treatment with lactate and ketones causes cancer cells to express gene profiles associated with “stemness.” They believe that these gene signatures could, in turn, predict poor clinical outcome in breast cancer patients.

The new arrays, scheduled to launch later this month, will enable researchers to examine alternately expressed exons, and are in line with Agilent's effort to build its portfolio in the gene expression market.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.